The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin
Increased use of azithromycin (AZ) in treating infections associated with coronavirus disease 2019 (COVID‐19) and reports of increased incidence of prolonged corrected QT (QTc) interval associated with AZ used with hydroxychloroquine prompted us to review the latest evidence in the literature, prese...
Main Authors: | Jack Cook, Milton L. Pressler, Bharat Damle, Demissie Alemayehu, Charles A. Knirsch |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12867 |
Similar Items
-
Risk of Cardiovascular Effects with Azithromycin
by: Ramachandran Kumaresan, et al.
Published: (2015-01-01) -
The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis.
by: Ahmed El-Tahtawy, et al.
Published: (2008-01-01) -
Use of microminipigs for unveiling unknown mechanisms of azithromycin-induced cardiovascular death
by: Ai Goto, et al.
Published: (2018-11-01) -
The Story of Azithromycin
by: Banić Tomišić, Z.
Published: (2011-12-01) -
Azithromycin (Zithromax®)
by: James M. McCarty
Published: (1996-01-01)